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(+31) 30-Purpose: To investigate the association between prostate specific antigen (PSA) bounce and disease outcome after
prostate brachytherapy.
Methods and Materials: We analyzed 975 patients treated with 125I implantation monotherapy between 1992 and
2006. All patients had tumor Stage#2c, Gleason score#7 prostate cancer, a minimum follow-up of 2 years with at
least four PSAmeasurements, and no biochemical failure in the first 2 years.Median follow-upwas 6 years. Bounce
was defined as a PSA elevation of +0.2 ng/mL with subsequent decrease to previous nadir. We used the Phoenix +2
ng/mL definition for biochemical failure. Additional endpoints were disease-specific and overall survival. Multi-
variate Cox regression analysis was performed to adjust for potential confounding factors.
Results: Bounce occurred in 32% of patients, with amedian time to bounce of 1.6 years.More than 90% of bounces
took place in the first 3 years after treatment and had disappeared within 2 years of onset. Ten-year freedom from
biochemical failure, disease-specific survival, and overall survival rates were, respectively, 90%, 99%, and 88% for
the bounce group and 70%, 93%, and 82% for the no-bounce group. Only 1 patient (0.3%) died of prostate cancer
in the bounce group, compared with 40 patients (6.1%) in the no-bounce group. Adjusted for confounding, a 70%
biochemical failure risk reduction was observed for patients experiencing a bounce (hazard ratio 0.31; 95% con-
fidence interval 0.20–0.48).
Conclusions: A PSA bounce after prostate brachytherapy is strongly related to better outcome in terms of bio-
chemical failure, disease-specific survival, and overall survival.
 2012 Elsevier Inc.
Bounce, PSA spike, Transient PSA elevation, Brachytherapy, Prostate cancer.
Open access under the Elsevier OA license.INTRODUCTION
Prostate specific antigen (PSA) levels after definitive
treatment for prostate cancer are an important source of in-
formation concerning disease status and treatment success.
After any form of radiation treatment, a steady decline of
serum PSA can be observed until usually a low level
remains. A subsequent rise of PSA generally is suggestive
of disease recurrence and, if the increase exceeds 2 ng/mL,
is termed biochemical failure (BF) (1). However, in up to
40% of patients treated with a form of radiotherapy (2),
a transient rise in PSA levels is observed, without apparent
disease recurrence and with subsequent normalization of
PSA values. This is called a PSA bounce.
To date, no conclusive evidence-based explanation for the
bouncing behavior of PSA exists. Precipitating factors sucht requests to: Karel A. Hinnen, M.D., Department of Ra-
ncology, University Medical Center Utrecht, P.O. Box
08 GA, The Netherlands. Tel: (+31) 88-7550474; Fax:
2581226; E-mail: KAHinnen@Gmail.com
883as ejaculations or instrumentation are known to cause some
PSA fluctuation (3), and the physiologic variability of PSA
assays in healthy test subjects was found to be considerable
(4). A small fraction of bounces may be caused by such fac-
tors; however, they fail to provide a complete explanation.
For prostate brachytherapy, recent studies concluded that
the occurrence of a PSAbouncewas related to increased free-
dom fromBF,which can not be explained by any of the above
mechanisms (5, 6). However, other studies did not find the
same association (7, 8). These inconsistent results might be
caused by several factors, such as differences in isotopes
used (9), a difference in bounce definition, and different
selection criteria.
More importantly, however, until now outcome for studies
on bounce and brachytherapy have only been reported as BF,Presented in part at the 29th Annual Meeting of the European So-
ciety for Therapeutic Radiology and Oncology, September 12–16,
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survival in relation to bounce.
If indeed bounce is related to improved outcome after bra-
chytherapy, the occurrence of a bounce will be an important
indicator in follow-up and may even become a parameter of
treatment success. Therefore, the purpose of this studywas to
determine the association between bounce and disease
outcome after prostate brachytherapy, as BF but also as
disease-specific and overall survival, in a large prostate
cancer brachytherapy cohort.METHODS AND MATERIALS
The study population consisted of patients with locally confined
prostate cancer, treated with 125I brachytherapy between 1992 and
September 2006 at the Department of Radiotherapy, University
Medical Center Utrecht, in the Netherlands. Clinical information
of all patients treated in this period was prospectively recorded in
a database. Study selection criteria included a minimum of four
available PSA determinations, at least 2 years of follow-up, no pros-
tate cancer–related supplementary surgery or external-beam radio-
therapy, and no BF in these first 2 years. The final analysis was
performed on a total of 975 patients. The 125I implantation procedure
was based on a transrectal ultrasound–guided approach, with
a planned total dose of 144 Gy (10). Both stranded seed as well as
loose seed implants were used interchangeably. From 1998, routine
volume studies and preplanning were performed in all patients, and
three-dimensional (3D) ultrasound–based intraoperative planning
was introduced in 2000. Starting in 2003, patients received preim-
plant MRI scans, which could be fused with 3D ultrasound to facil-
itate intraoperative prostate delineation. The implantation technique
and procedure have been described in more detail in previous work
(11, 12). Patientswith a prostatevolumeexceeding50 cm3 received6
months of preimplant androgen deprivation therapy to downsize theTable 1. Baseline characteristics of the study
Baseline characteristics Bounce
Patients (n) 314
Age (y) 64  6.5
PSA at diagnosis 7.7 (5.6–11.0)
Tumor stage
#2A 290 (92)
$2B 24 (8)
Gleason score
<7 169 (54)
7 142 (46)
Risk class
Low 107 (34)
Intermediate 146 (47)
High 58 (19)
Androgen deprivation therapy 63 (20)
Transurethral prostate resection 26 (8)
Prostate volume (cm3) 36  10.8
Seeds implanted 73  16.3
Follow-up (y) 6.2 (4.5–8.0)
No. of PSA measurements 9 (7–12)
D90 at implantation* (n = 142) 155 (134–178)
Abbreviations: IQR = interquartile range; PSA = prostate specific anti
volume, as measured 4 weeks after implantation.
Values are mean  SD, median (IQR), or number (percentage).
* Dosimetry was only available since the end of 2004.prostate for implantation feasibility. Androgen deprivation therapy
consisted of a luteinizing hormone-releasing hormone agonist.
Our primary endpoint was BF, according to the Phoenix defini-
tion (+2 ng/mL rise of PSA above nadir) (1). Our secondary end-
points were disease-specific survival and overall survival. The
follow-up consisted of visits every 3 months during the first year
and half-yearly visits thereafter, at which point PSA levels were de-
termined. Date of death was established through the national
population registry, and cause of death was determined by contact-
ing the related general practitioner or by means of the hospital
information system. Death with distant metastasis was considered
as death from disease.
Different bounce definitions exist (2), with different threshold
values, typically in the range of+0.1 ng/mL to+0.5 ng/mL.We report
our results according to the +0.2 ng/mL definition, which is the most
widely used bounce threshold in literature. To investigate the impact
of a higher bounce threshold on our results, we performed an addi-
tional sensitivity analysis with the +0.5 ng/mL threshold definition.
In addition, our bounce definition included a normalization of
PSA values to or below previous nadir. We defined no time span
for bounce occurrence.
Risk stratification was performed according to Ash et al. (13).
Thus, defining low risk as maximum tumor (T) Stage 2a, Gleason
score 6, and initial PSA level <10 ng/mL. Intermediate risk was
defined as either T Stage 2b/2c, Gleason score 7, or initial PSA level
10–20 ng/mL combined with two low-risk features. High risk was
defined as two or three intermediate-risk factors or initial PSA level
>20 ng/mL. Tumor staging was based on the 2002 version of the
American Joint Committee on Cancer system.
Baseline characteristics were reported as means  SD, medians
with interquartile range (IQR), or as percentages. The associations
between the occurrence of bounce and clinical as well as pathologic
data were examined with Student’s t-test for parametric variables
and with the Mann-Whitney test in case of categoric or nominal
variables. The Kaplan-Meier method was used for comparing
patients with or without a bounce and the time to the definedpatients divided by bounce occurrence
No bounce p Total
661 975
67  6.4 <0.001 66  6.6
9.1 (6.3–13.3) <0.001 8.6 (6.0–12.2)
<0.001
562 (85) 852 (87)
99 (15) 123 (13)
0.024
301 (46) 470 (48)
360 (54) 502 (52)
<0.001
155 (24) 262 (27)
281 (43) 427 (44)
221 (34) 279 (29)
118 (18) ns 181 (19)
61 (9) ns 87 (9)
35  11.6 ns 35  11.4
70  18 <0.001 71  17.6
5.8 (4.3–8.2) ns 6.0 (4.4–8.1)
7 (5–10) <0.001 8 (6–11)
162 (139–180) ns 159 (137–179)
gen; D90 = minimal delivered dose (in Gy) to 90% of the prostate
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compared with the log–rank test for censored data.
To adjust for baseline differences and potential confounding fac-
tors, univariate and multivariate Cox proportional hazards regression
analyses were performed. Considered potential confounding factors
were age, prebrachytherapy androgen deprivation therapy, prior tran-
surethral prostate resection, the number of implanted seeds, prostate
volume, treatment year, andprostate cancer risk class.ThevariablesT
stage, PSA at diagnosis, and Gleason score all are represented in the
risk-group variable and were therefore omitted. According to the
multivariate Cox proportional hazards regression model, in which
at each time point an estimation of the risk, adjusted for baseline
differences is calculated, figures were plotted to observe the indepen-
dent effect of bounce. Hazard ratios (HR) and 95% confidence inter-
vals (CI) were calculated, and statistical significance was considered
if p < 0.05. All analyses were performed with the Statistical Package
for Social Sciences, version 16.0.2 (SPPS, Chicago, IL).Fig. 1. Kaplan-Meier curve for prostate-specific antigen bounce
and freedom from biochemical failure.
Table 2. Multivariate Cox regression analysis of bounce and
biochemical failure, adjusted for baseline differences
Variable Hazard ratio
95% confidence
interval p
Age 1.01 0.99–1.03 ns
Androgen deprivation
therapy
0.90 0.59–1.36 ns
Seeds implanted 1.01 1.00–1.02 ns
Prostate volume (cm3) 0.98 0.97–1.00 ns
Year of treatment 0.88 0.83–0.93 <0.01
Risk class
Intermediate 2.74 1.62–4.65 <0.01
High 5.96 3.60–9.86 <0.01
Bounce 0.31 0.20–0.48 <0.01RESULTS
Baseline characteristics are presented in Table 1, subdi-
vided into 314 patients with a bounce (32%) and 661 without
a bounce (68%). In general, patients in the bounce group
were younger and more often had low-risk prostate cancer.
There was no difference in follow-up, with a mean follow-
up of 6.5 years (range 2.3–17.9 years); approximately one
third of the total patient population was treated in the
previous decade and therefore had more than 10 years of
follow-up. The median PSA bounce peak was 1.7 ng/mL
(IQR 1.0–2.8). Forty-seven patients (4.8%) had a bounce
peak exceeding the BF definition. The median time to
bounce was 1.6 years (IQR 1.0–2.0 years), and more than
90% of bounces occurred in the first 3 years after implanta-
tion. The median bounce duration, defined as the time
between onset of bounce and return to nadir, was 1 year
(IQR 0.5–1.25 years), with more than 90% of bounces hav-
ing disappeared in less than 2 years from onset.
We observed 24 patients with a BF in the bounce group
(7.6%) vs. 181 (27.4%) in the no-bounce group. In the
bounce group only 1 patient (0.3%) died of prostate cancer,
compared with 40 patients (6.1%) in the no-bounce group.
Figure 1 shows the Kaplan-Meier curve for freedom from
BF for patients with and without a bounce. The log–rank
tests for bounce and BF, disease-specific survival, and over-
all survival were all statistically significant (p < 0.01).
Univariate Cox proportional hazards regression for bounce
and BF showed an HR of 0.22 (95% CI 0.14–0.34). After ad-
justing for potential confounders, the multivariate Cox pro-
portional hazards model still provided a 69% BF risk
reduction for patients with a bounce (HR 0.31; 95% CI
0.20–0.48). Results are shown in Table 2. Figures 2–4 show
the corresponding Cox proportional hazards curves
(adjusted for confounders) for bounce and, respectively,
freedom from BF, disease-specific survival, and overall sur-
vival. The accompanying 10-year rates for freedom from
BF, disease-specific survival, and overall survival were, re-
spectively, 90%, 99%, and 88% for the bounce group and
70%, 93%, and 82% for the no-bounce group.When substituting the +0.2-ng/mL for the +0.5-ng/mL
bounce threshold, the bounce rate changed from 32% to
24%. The HR (adjusted for confounders) of bounce and
BF changed slightly to 0.34 (95% CI 0.21–0.55). The 10-
year rates for freedom from BF, disease-specific survival,
and overall survival also changed marginally (data not
shown), with log–rank tests remaining significant (p < 0.01).DISCUSSION
The presented data show a very strong association be-
tween the occurrence of a PSA bounce and BF. Adjusted
for potential confounding factors, a near 70% BF risk reduc-
tion is observed for patients experiencing a bounce after bra-
chytherapy compared with patients without a bounce. Even
more importantly, a significant association was found be-
tween bounce and death from disease, with only 1 patient
(0.3%) dead of prostate cancer in the bounce group, com-
pared with 40 patients (6.1%) in the no-bounce group.
Fig. 4. Multivariate Cox regression curve for prostate-specific
antigen bounce and overall survival, adjusted for baseline
differences.
Fig. 2. Multivariate Cox regression curve for prostate-specific
antigen bounce and freedom from biochemical failure, adjusted
for baseline differences.
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part influenced the low outcome of the no-bounce group;
however, large differences still exist between the bounce
and no-bounce group, as was calculated with the multivariate
Cox regression analysis. The overall BF, disease-specific sur-
vival, and overall survival rates have been previously de-
scribed (12), and for low- and intermediate-risk patients,
outcomes are comparable to data from the literature. High-
risk subgroup comparison is more difficult owing to its large
heterogeneity and the resulting composition differences
between studies.Fig. 3. Multivariate Cox regression curve for prostate-specific
antigen bounce and disease-specific survival, adjusted for baseline
differences.Furthermore, it must be taken into account that the out-
comes of this study are partly based on a patient population
treated 2 decades ago. The results of patients treated in the
last decade have much improved (12) owing to, for example,
increased diagnostic accuracy, improved implant quality, and
dosimetric quality control. This can also be seen in Table 2,
where treatment year is a strong independent predictor of out-
come. Nonetheless, most important is to note that the differ-
ence in outcome between the bounce and no-bounce group is
independent of risk group, age, or treatment period.
After careful consideration, we decided to exclude from
analysis patients with a disease recurrence in the first 2 years
after treatment. These patients by definition have no chance
to bounce and subsequently bias the outcome. All patients
analyzed in our study had at least four PSA determinations
with a minimum follow-up of 2 years, thus providing an
equal chance to bounce for all patients. Indeed, up to 75%
of patients bounced in those first 2 years. However, when ex-
trapolating our results to the general patient population, that
includes patients with early BF, the difference in prognosis
between patients with or without a bounce would even be
much larger. When defining a cutoff value for bounce, it is
essential to choose a sensitive value, higher than the interas-
say variation. In the literature, the interassay mean coeffi-
cient of variation, specifically for a PSA <2 ng/mL, was
reported to be approximately 2.8% for patients without
prostate cancer (14). In addition, the general day-to-day var-
iation of PSA assays at our in-house laboratory, where the
majority of assays has been performed, was ascertained at
5–7%. To conclude, a +0.2-ng/mL definition for bounce
seems suitable to differentiate bounce from test variations.
Nevertheless, we repeated our calculations with the various
bounce thresholds found in the literature, ranging from +0.2
ng/mL to +0.5 ng/mL. The differences in outcome between
PSA bounce after brachytherapy is related to OS d K. A. HINNEN et al. 887definitions proved to be marginal and resulted in the same
conclusions concerning the relation of bounce and outcome.
The bounce phenomenon can be observed after both bra-
chytherapy as well as external-beam radiotherapy. However,
we chose only to include brachytherapy studies in our liter-
ature overview because of differences between either treat-
ment, such as the higher effective dose to the prostate,
dose inhomogeneity, and a suggested higher bounce rate in
brachytherapy (7, 15).
Three previous studies (5–7) reported on bounce and
brachytherapy as monotherapy. The study of Patel et al.
(5) and the more recent study from the same center by Ciezki
et al. (6) also observed an improved BF outcome for patients
experiencing a bounce. Ciezki et al. (6) (n = 162) used the
same BF and bounce definition and had follow-up compara-
ble to that in the present study. They did report a somewhat
higher bounce rate of 46% and chose a minimum PSA
follow-up period of 5 years. In contrast, Stock et al. (7)
(n = 373) used various bounce definitions, with none
showing an association between bounce and BF. Follow-up
was shorter, and a number of patients received 103Pd sources,
and a difference in isotope has been previously shown to
affect bounce occurrence (8).
The studies of Cavanagh et al. (16) and Critz et al. (17)
reported on a combination of brachytherapy with external-
beam radiotherapy. Cavanagh et al. (16) (n = 591) did not
find an association between bounce and BF. In the study of
Critz et al. (17) (n = 1011), a significant association between
bounce and BF rate was found. However, the authors con-
cluded that this was a biased result due to inclusion of
patients with early BF; unfortunately, no additional analyses
to overcome this bias were performed. Although follow-up
was comparable to that in the present study, different bounce
(+0.1 ng/mL) and BF definitions were used. This affects the
bounce likelihood and could also have influenced the study
outcome. Furthermore, the use of external-beam radiother-
apy limits the comparability with the present study.
Strengths of our study include, among others, the addition
of the secondary endpoints disease-specific survival and
overall survival. None of the above-mentioned studies
reported on these endpoints.
Although BF is generally considered a reasonable surro-
gate outcome for prostate cancer–specific mortality (18),
death due to prostate cancer remains the more relevant
clinical endpoint. Unlike BF, disease-specific survival is
less susceptible to loss to follow-up because of the possibility
to ascertain death and cause of death retrospectively through
hospital information systems and national registries. Addi-
tionally, BF is more prone to information bias (i.e., potential
dissimilarities in PSA testing frequency during follow-up
could affect the diagnosis of BF). Moreover, the lack of uni-
formity in BF definitions through time makes it much more
difficult to compare studieswith a difference inBF definition.
Limitations of our study include the partial availability of
dose parameters. These parameters were calculated onward
from the end of 2004 and could therefore not be accounted
for in our main analyses. The value of dosimetry has onlybeen established in the last decade and therefore is unavail-
able when analyzing long-term data that are necessary for
calculating overall and disease-specific survival. Nonethe-
less, in 144 patients dosimetry was available, and for this
subset no association between dose and bounce occurrence
could be established. Follow-up was too short for subanaly-
sis of bounce and BF in these 144 patients. External valida-
tion of our findings in a 125I brachytherapy cohort with
extensive follow-up for patients with dosimetric data will
be required to investigate whether the received dose influ-
ences the bounce occurrence and whether a lower implant
quality can partly account for the worse outcome seen in
patients without a bounce.
Patients in the bounce group had a slightly higher PSA test-
ing frequency, probably due to increased follow-up intensity,
although duration of follow-up was equal in both groups.
Prostate-specific antigen bounces are an important prob-
lem for both clinicians and patients because of BF false calls.
This results in unnecessary anxiety in patients and
a treatment dilemma for doctors. Our results confirm that
the average bounce occurs earlier than BF; 90% of bounces
occurred in the first 3 years, although considerable overlap
exists. In the entire cohort of our brachytherapy patients,
the risk of a BF false call was <5%, and most bounces had
disappeared within 2 years. The mechanism behind the
bounce phenomenon is still unknown. Different hypotheses
are mentioned in the literature, but no evidence-based expla-
nation exists to date. It is supposed that bounce may primar-
ily be a delayed radiation effect on remaining prostate tissue
(19). This hypothesis was based on the time frame of bounce
occurrence coinciding with late urinary symptoms at 1 to 2
years after treatment. However, a recent publication from
our center on health-related quality of life in brachytherapy
patients showed a near-baseline resolution of urinary symp-
toms within the first year (20). In a second theory, Akyol
et al. (2) describe the relationship between rising testoster-
one levels and bounce occurrence, after a combination of
external-beam radiotherapy and short-term androgen depri-
vation therapy. Not only the androgen deprivation therapy it-
self but also supposed radiation effects (e.g., due to scatter
on the testicles) were hypothesized to influence testosterone
kinetics and consequently result in PSA bouncing (2). Al-
though in our study only approximately 20% of patients
received androgen deprivation therapy before treatment, its
usewas as common in both the bounce and no-bounce group,
and we could not confirm a relation between androgen dep-
rivation therapy and bounce occurrence.
A third hypothesis points out that sexual activity and pros-
tate instrumentation have a large impact on PSA fluctuations
and may be a cause of bounce (3). A slightly younger age is
seen throughout literature for patients with a bounce com-
pared with patients without a bounce; perhaps higher sexual
activity can account for the higher frequency of younger age
in the bounce group. The above-mentioned factors will un-
deniably have some influence on PSA variation; and it is
known that the physiologic variability of PSA assays in
healthy individuals is substantial (4). However, none of the
888 I. J. Radiation Oncology d Biology d Physics Volume 82, Number 2, 2012above-mentioned hypotheses can explain why bounce is
found to be related to better survival. Rosser et al. (21) pro-
posed that a PSA bounce may be caused by the physiologic
response of prostate tissue to radiation, with a transition of
sublethal to lethal cellular damage resulting in en-mass
cell death and a sudden release of high PSA levels into the
bloodstream. Consequently, the absence of bounce may sug-
gest a lesser treatment effect with possibly a more malignant
cell line that is less responsive to radiation. Although this hy-
pothesis matches our findings, it will have to be supported by
future evidence.
In a recent study by Kirilova et al. (22) patients with
a bounce after 125I brachytherapy were examined using 3DMR spectroscopy. They found that an ordinary bounce was
accompanied by diffuse metabolic activity that was not
related to residual malignancy, whereas in case of recurrence
more focal activity was observed. Consequently, it was pro-
posed that in certain cases 3D MR spectroscopy might be
used to help clinicians differentiate true bounce from early
disease recurrence.
To conclude, although the bounce phenomenon is clearly
not yet properly understood and may in part be
contaminated because of other causes of PSA fluctuation,
a significant and clinically relevant relation was seen
between bounce occurrence and disease outcome after
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